Resecable intrahepatic cholangiocarcinoma diagnosed during follow up for endocrine neoplasia

Read full article
Article Title: Resecable intrahepatic cholangiocarcinoma diagnosed during follow up for endocrine neoplasia
Authors: Ginghina O., Iosifescu R., Gadea C., Spanu A., Negrei C., Toderescu C.D., Jinescu G., Nicolescu F.
Affiliation: ”Sf. Ioan” Hospital, Department of Oncological Surgery, Bucharest, Romania
Department of Toxicology, “Carol Davila” University of Medicine and Pharmacy, 6, Traian Vuia Street, Bucharest, Romania
”Vasile Goldis” Western University of Arad, The Faculty of General Medicine, Pharmacy and Dental Medicine, 91-93, L. Rebreanu Str., Arad, Romania
Department of General Surgery, “Spitalul Clinic de Urgenta”, “Carol Davila” University of Medicine and Pharmacy, 8, Floreasca street, Bucharest, Romania
Abstract: Intrahepatic cholangiocarcinoma is one of the most important primary liver tumours. Because of its aggressiveness, the prognosis for intrahepatic cholangiocarcinoma is discouraging and the expectancy for improvement is quite low. More effective therapy consists of curative resection, which is also the sole therapy resulting in longer patient survival under disease free conditions. A 74-year-old woman, with a total thyroidectomy for papillar carcinoma was diagnosed with a hepatic mass. The MRI exam revealed an expanded-infiltrative process in the 4th hepatic segment, non-capsulated, hypointense on T1-weighted images and hyperintense on T2-weighted-images, with central scar, suggesting peripheral intrahepatic cholangiocarcinoma, with hepatic hilum lymph nodes enlargement. Cholecystectomy was performed, and the cystic duct was sectioned away from the common bile duct. Hepatic hilum lymphadenectomy was performed at the end of the procedure. After 6 month, hepatic and renal functions were normal. It has been observed that the only intervention able to attain patient survival for longer periods is intrahepatic cholangiocarcinoma curative resection.
Keywords: hepatectomy, intrahepatic cholangiocarcinoma
References:
*Correspondence: Carolina Negrei, Department of Toxicology, “Carol Davila” University of Medicine and Pharmacy, 6, Traian Vuia Street, Bucharest, Romania, carol_n2002@hotmail.com